This was the stock's third consecutive day of losses.

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus ...

In a report released today, Laura Chico from Wedbush maintained a Hold rating on Biogen (BIIB – Research Report), with a price target of $121.00. The company’s shares closed y ...

The Bureau of Labor Statistics stated on June 11 that consumer prices increased less than anticipated in May given that President Donald Trump ...

Since McKinney Health burst onto the scene in 2022, it has been carving out its place at the intersection of health and life.

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $190.82, a high estimate of ...

Shares of Biogen Inc. BIIB shed 1.79% to $133.06 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the Dow Jones Industrial Average DJIA remaining mostly ...

Looking at licensing deals struck in the past 10 years, Jefferies found that many Big Pharmas do not ultimately follow ...